Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.
https://www.pharmalive.com/wp-content/uploads/2023/08/BioSpaceNovoNordisk8-30-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-10-11 08:51:432023-10-11 09:05:48Novo ends semaglutide kidney study early due to strong efficacy signals
